These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 23542991)

  • 41. Contribution of human factors for the review of automatically detected ADE.
    Leroy N; Luyckx M; Lecocq P; Marcilly R; Beuscart-Zéphir MC
    Stud Health Technol Inform; 2009; 148():170-80. PubMed ID: 19745248
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ontology-based knowledge management for personalized adverse drug events detection.
    Cao F; Sun X; Wang X; Li B; Li J; Pan Y
    Stud Health Technol Inform; 2011; 169():699-703. PubMed ID: 21893837
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An empirical model to estimate the potential impact of medication safety alerts on patient safety, health care utilization, and cost in ambulatory care.
    Weingart SN; Simchowitz B; Padolsky H; Isaac T; Seger AC; Massagli M; Davis RB; Weissman JS
    Arch Intern Med; 2009 Sep; 169(16):1465-73. PubMed ID: 19752403
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Parameter selection for and implementation of a web-based decision-support tool to predict extubation outcome in premature infants.
    Mueller M; Wagner CL; Annibale DJ; Knapp RG; Hulsey TC; Almeida JS
    BMC Med Inform Decis Mak; 2006 Mar; 6():11. PubMed ID: 16509967
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sleep and kangaroo care: clinical practice in the newborn intensive care unit: where the baby sleeps..
    Smith KM
    J Perinat Neonatal Nurs; 2007; 21(2):151-7. PubMed ID: 17505236
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The expert explorer: a tool for hospital data visualization and adverse drug event rules validation.
    Băceanu A; Atasiei I; Chazard E; Leroy N;
    Stud Health Technol Inform; 2009; 148():85-94. PubMed ID: 19745238
    [TBL] [Abstract][Full Text] [Related]  

  • 47. User-friendly computerized quality assurance program for regionalized neonatal care.
    Donn SM; Gates MR; Kiska DJ
    J Perinatol; 1993; 13(3):190-6. PubMed ID: 8345381
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Constructing Clinical Decision Support Systems for Adverse Drug Event Prevention: A Knowledge-based Approach.
    Koutkias V; Kilintzis V; Stalidis G; Lazou K; Collyda C; Chazard E; McNair P; Beuscart R; Maglaveras N
    AMIA Annu Symp Proc; 2010 Nov; 2010():402-6. PubMed ID: 21347009
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An architecture for multi-dimensional temporal abstraction and its application to support neonatal intensive care.
    Stacey M; McGregor C; Tracy M
    Annu Int Conf IEEE Eng Med Biol Soc; 2007; 2007():3752-6. PubMed ID: 18002814
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Graphical user interface for a neonatal parenteral nutrition decision support system.
    Peverini RL; Beach DS; Wan KW; Vyhmeister NR
    Proc AMIA Symp; 2000; ():650-4. PubMed ID: 11079964
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Informatics tools for the development of action-oriented triggers for outpatient adverse drug events.
    Mull HJ; Nebeker JR
    AMIA Annu Symp Proc; 2008 Nov; 2008():505-9. PubMed ID: 18999297
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role and experience determine decision support interface requirements in a neonatal intensive care environment.
    Ewing G; Freer Y; Logie R; Hunter J; McIntosh N; Rudkin S; Ferguson L
    J Biomed Inform; 2003; 36(4-5):240-9. PubMed ID: 14643719
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Why open drug discovery needs four simple rules for licensing data and models.
    Williams AJ; Wilbanks J; Ekins S
    PLoS Comput Biol; 2012; 8(9):e1002706. PubMed ID: 23028298
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Integration of drug dosing data with physiological data streams using a cloud computing paradigm.
    Bressan N; James A; McGregor C
    Annu Int Conf IEEE Eng Med Biol Soc; 2013; 2013():4175-8. PubMed ID: 24110652
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adverse drug reactions in neonates and infants: a population-tailored approach is needed.
    Allegaert K; van den Anker JN
    Br J Clin Pharmacol; 2015 Oct; 80(4):788-95. PubMed ID: 24862557
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adverse drug event prevention in neonatal care: a rule-based approach.
    Lazou K; Farini M; Koutkias V; Drossou V; Maglaveras N; Bassiliades N
    Stud Health Technol Inform; 2013; 186():170-4. PubMed ID: 23542991
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Towards a standardised representation of a knowledge base for adverse drug event prevention.
    Koutkias V; Lazou K; de Clercq P; Maglaveras N
    Stud Health Technol Inform; 2011; 166():139-47. PubMed ID: 21685619
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Knowledge engineering for adverse drug event prevention: on the design and development of a uniform, contextualized and sustainable knowledge-based framework.
    Koutkias V; Kilintzis V; Stalidis G; Lazou K; Niès J; Durand-Texte L; McNair P; Beuscart R; Maglaveras N
    J Biomed Inform; 2012 Jun; 45(3):495-506. PubMed ID: 22326287
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PSIP: an overview of the results and clinical implications.
    Beuscart R
    Stud Health Technol Inform; 2011; 166():3-12. PubMed ID: 21685604
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.